<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">693492</article-id><article-id pub-id-type="doi">10.26442/20751753.2026.7.203614</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The effect of shock wave therapy on endothelial function and cavernous blood flow: Doppler ultrasonography with functional tests</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние ударно-волновой терапии на эндотелиальную функцию и кавернозный кровоток: ультразвуковая допплерография с функциональными пробами</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6225-5872</contrib-id><name-alternatives><name xml:lang="en"><surname>Burdin</surname><given-names>Konstantin A.</given-names></name><name xml:lang="ru"><surname>Бурдин</surname><given-names>Константин Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate Student</p></bio><bio xml:lang="ru"><p>аспирант каф. урологии и андрологии</p></bio><email>burdinuco@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1050-6198</contrib-id><name-alternatives><name xml:lang="en"><surname>Kyzlasov</surname><given-names>Pavel S.</given-names></name><name xml:lang="ru"><surname>Кызласов</surname><given-names>Павел Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., проф. каф. урологии и андрологии</p></bio><email>burdinuco@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center – Burnazyan Federal Medical Biophysical Center</institution></aff><aff><institution xml:lang="ru">ФГБУ «Государственный научный центр Российской Федерации – Федеральный медицинский биофизический центр им. А.И. Бурназяна» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-07-16" publication-format="electronic"><day>16</day><month>07</month><year>2026</year></pub-date><volume>28</volume><issue>7</issue><issue-title xml:lang="en">Women’s and men’s health</issue-title><issue-title xml:lang="ru">Женское и мужское здоровье</issue-title><fpage>500</fpage><lpage>507</lpage><history><date date-type="received" iso-8601-date="2025-10-16"><day>16</day><month>10</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-12-15"><day>15</day><month>12</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/693492">https://consilium.orscience.ru/2075-1753/article/view/693492</self-uri><abstract xml:lang="en"><p><bold>Aim. </bold>To evaluate the effect of low-intensity extracorporeal shock wave therapy (Li-ESWT) on endothelial function of the cavernosal arteries and penile blood flow in men with vasculogenic erectile dysfunction (ED) using Doppler ultrasonography with pharmacological stimulation.</p> <p><bold>Materials and methods.</bold> This single-center prospective study included 48 men aged 18–65 years with chronic vasculogenic ED and cardiovascular risk factors, including arterial hypertension (52%), dyslipidemia (42%), obesity (31%), and type 2 diabetes mellitus (21%). Focused Li-ESWT was applied (2000 pulses/session, ~0.10 mJ/mm², 3–5 Hz, twice weekly) for 6–12 sessions targeting the penile shaft and crura. Treatment efficacy was evaluated by Duplex Doppler ultrasonography with intracavernosal alprostadil (10 µg) stimulation using (PSV – peak systolic velocity, EDV – end-diastolic velocity, RI – resistance index) and by International Index of Erectile Function (IIEF-5) at baseline, 1 month, and up to 6 months after therapy.</p> <p><bold>Results. </bold>Significant improvement in cavernous hemodynamics was observed: PSV increased from 21.4±8.7 to 32.8±11.5 cm/s (<italic>p</italic>&lt; 0.001), EDV decreased from 6.2±3.1 to 4.0±2.5 cm/s (<italic>p</italic>=0.01), and RI increased from 0.71±0.11 to 0.86±0.08 (<italic>p</italic>&lt; 0.001). Mean IIEF-5 score improved from 11.8±4.5 to 17.2±5.0 (<italic>p</italic>&lt; 0.001), with clinically meaningful improvement (≥4 points) observed in 62.5% of patients; 21% of those with moderate ED achieved normal erectile function. Patients without severe atherosclerosis of cavernosal arteries demonstrated the most pronounced response, whereas long-standing diabetes and advanced vascular changes were associated with reduced treatment efficacy. No adverse events were recorded. Two clinical cases illustrate a complete response in moderate ED and a partial response in diabetic atherosclerotic ED.</p> <p><bold>Conclusion. </bold>Li-ESWT significantly enhances endothelial function and penile blood flow in vasculogenic erectile dysfunction, confirmed by objective Doppler parameters and clinical scores. The best outcomes occur in patients with preserved vascular reserve, whereas severe structural vascular disease may require combined or repeated regenerative interventions. Standardized protocols and long-term prospective studies are warranted.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель. </bold>Оценить влияние низкоинтенсивной ударно-волновой терапии (УВТ) на эндотелиальную функцию кавернозных артерий и параметры кавернозного кровотока у мужчин с васкулогенной эректильной дисфункцией (ЭД) на основе ультразвуковой допплерографии с функциональными пробами.</p> <p><bold>Материалы и методы. </bold>В одноцентровое проспективное исследование включены 48 мужчин 18–65 лет с хронической ЭД сосудистого генеза и сопутствующими факторами риска, среди которых артериальная гипертензия (52%), дислипидемия (42%), ожирение (31%) и сахарный диабет (СД) 2-го типа (21%). Применяли фокусированную УВТ (2000 импульсов/сеанс, ~0,10 мДж/мм<sup>2</sup>, 3–5 Гц, 2 сеанса в неделю) курсом 6–12 процедур с воздействием на ствол и ножки кавернозных тел. Эффективность оценивали по данным допплерографии с фармакологической пробой алпростадилом (PSV – пиковой систолической скорости, EDV – конечной диастолической скорости, RI – индексу резистентности) и шкале Международного индекса эректильной функции (IIEF-5) до лечения, через 1 мес и при наблюдении до 6 мес.</p> <p><bold>Результаты. </bold>Отмечено значимое улучшение гемодинамических показателей кавернозных артерий: PSV увеличилась с 21,4±8,7 до 32,8±11,5 см/с (<italic>p</italic>&lt; 0,001), EDV снизилась с 6,2±3,1 до 4,0±2,5 см/с (<italic>p</italic>=0,01), RI возрос с 0,71±0,11 до 0,86±0,08 (<italic>p</italic>&lt; 0,001). Средний балл IIEF-5 повысился с 11,8±4,5 до 17,2±5,0 (<italic>p</italic>&lt; 0,001), при этом клинически значимое улучшение (≥4 балла) отмечено у 62,5% пациентов; у 21% больных с умеренной ЭД достигнуты нормальные показатели эректильной функции. Наиболее выраженный эффект наблюдался при сохраненном сосудистом резерве, тогда как наличие СД и кавернозного атеросклероза снижало результативность терапии. Нежелательных явлений не зарегистрировано. Клинические примеры демонстрируют полный ответ на УВТ у пациента с умеренной ЭД и частичный – при длительном СД и выраженном атеросклерозе.</p> <p><bold>Заключение. </bold>Низкоинтенсивная УВТ способствует улучшению эндотелиальной функции и кавернозного кровотока у пациентов с васкулогенной ЭД, что подтверждается данными допплерографии и клинических шкал. Терапия наиболее эффективна при отсутствии тяжелых структурных изменений сосудов; при выраженной сосудистой патологии целесообразно применение комбинированных подходов и повторных курсов. Требуются стандартизация протоколов и расширение длительных наблюдений.</p></trans-abstract><kwd-group xml:lang="en"><kwd>erectile dysfunction</kwd><kwd>shockwave therapy</kwd><kwd>endothelial dysfunction</kwd><kwd>cavernous blood flow</kwd><kwd>penile Doppler sonography</kwd><kwd>functional test</kwd><kwd>alprostadil</kwd><kwd>peak systolic velocity</kwd><kwd>end-diastolic velocity</kwd><kwd>resistance index</kwd><kwd>International Index of Erectile Function</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>эректильная дисфункция</kwd><kwd>ударно-волновая терапия</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>кавернозный кровоток</kwd><kwd>допплерография полового члена</kwd><kwd>функциональная проба</kwd><kwd>алпростадил</kwd><kwd>пиковая систолическая скорость</kwd><kwd>конечная диастолическая скорость</kwd><kwd>индекс резистентности</kwd><kwd>Международный индекс эректильной функции</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Caretta N, De Rocco Ponce M, Minicuci N, et al. Efficacy of penile low-intensity shockwave treatment for erectile dysfunction: correlation with the severity of cavernous artery disease. Asian J Androl. 2021;23(5):462-7. DOI:10.4103/aja.aja_15_21</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lange M, Charles D, Kazeem A, et al. Is low-intensity shockwave therapy for erectile dysfunction a durable treatment option? Long-term outcomes of a randomized sham-controlled trial. Transl Androl Urol. 2024;13(10):2194-200. DOI:10.21037/tau-24-329</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol. 2012;187(5):1769-75. DOI:10.1016/j.juro.2011.12.117</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Fatima K, Abbas Z, Un-Noor A, et al. Efficacy of low-intensity extracorporeal shock wave therapy for erectile dysfunction: Updated meta-analysis of randomized trials. Future Sci OA. 2025;11(1):2511438. DOI:10.1080/20565623.2025.2511438</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Medrano-Sánchez EM, Peña-Cantonero B, Candón-Ballester P, et al. Effectiveness of low-intensity extracorporeal shock wave therapy in erectile dysfunction: An analysis of sexual function and penile hardness at erection (umbrella review). J Pers Med. 2024;14(2):177. DOI:10.3390/jpm14020177</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hayon S, Panken EJ, Bennett NE.Variations in low-intensity shockwave treatment protocols for erectile dysfunction: A review of the literature and guide to offering treatment. World J Mens Health. 2024;42(2):283-9. DOI:10.5534/wjmh.230105</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: A systematic review and meta-analysis. Int J Impot Res. 2019;31(3):177-94. DOI:10.1038/s41443-019-0117-z</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fojecki GL, Tiessen S, Osther PJ. Effect of low-energy linear shockwave therapy on erectile dysfunction – A double-blinded, sham-controlled, randomized clinical trial. J Sex Med. 2017;14(1):106-12. DOI:10.1016/j.jsxm.2016.11.307</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Sokolakis I, Dimitriadis F, Teo P, et al. The basic science behind low-intensity extracorporeal shockwave therapy for erectile dysfunction: A systematic scoping review of pre-clinical studies. J Sex Med. 2019;16(2):168-94. DOI:10.1016/j.jsxm.2018.12.016</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Salonia A, Bettocchi C, Boeri L, et al. Male sexual dysfunction: Summary of the 2021 EAU Guidelines on sexual and reproductive health. Eur Urol. 2021;80(3):333-57. DOI:10.1016/j.eururo.2021.06.007</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bocchino AC, Pezzoli M, Martínez-Salamanca JI, et al. Low-intensity extracorporeal shock wave therapy for erectile dysfunction: Myths and realities. Investig Clin Urol. 2023;64(2):118-25. DOI:10.4111/icu.20220327</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Aversa A, Crafa A, Greco EA, et al. The penile duplex ultrasound: How and when to perform it? Andrology. 2021;9(5):1457-66. DOI:10.1111/andr.13029</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sun GH, Han YF, Dai YT, et al. Color Doppler ultrasound results of erectile dysfunction patients after an intracavernosal injection of prostaglandin E1: An analysis of 9,109 cases. Transl Androl Urol. 2026;15(1):22. DOI:10.21037/tau-2025-650</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ravikanth R. Diagnostic categorization of erectile dysfunction using duplex color doppler ultrasonography and significance of phentolamine redosing in abolishing false diagnosis of venous leak impotence: A single center experience. Indian J Radiol Imaging. 2020;30(3):344-53. DOI:10.4103/ijri.IJRI_419_19</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Jung DC, Park SY, Lee JY. Penile Doppler ultrasonography revisited. Ultrasonography. 2017;37(1):16-24. DOI:10.14366/usg.17022</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Elgendi K, O’Neil B. The role of Doppler ultrasound in the evaluation of penile vascular erectile dysfunction. Sonic. 2024;6(1):e12403. DOI:10.1002/sono.12403</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Sudhindar PD, Olinger E, Sentell ZT, et al. Urinary renal epithelial cells can be used for NPHP1 phenotyping and a personalized therapeutic strategy. J Cell Sci. 2025;138(20):jcs264141. DOI:10.1242/jcs.264141</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Yao H, Wang X, Liu H, et al. Systematic review and meta-analysis of randomized controlled trials of Li-ESWT for erectile dysfunction. Am J Mens Health. 2022;16(2):15579883221087532. DOI:10.1177/15579883221087532</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Gallo L, Pecoraro S, Sarnacchiaro P.Adjuvant L-arginine 2,500 mg plus tadalafil 5 mg increases efficacy and duration of benefits of Li-ESWT: A randomized single-blind study with 1-year follow-up. Investig Clin Urol. 2022;63(1):83-91. DOI:10.4111/icu.20210317</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Rubino M, Ricapito A, Finati M, et al. Impact of low-intensity extracorporeal shockwave therapy on vascular parameters and sexual function in patients with arteriogenic erectile dysfunction. Asian J Androl. 2024;26(4):344-8. DOI:10.4103/aja202384</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Ma M, Yu B, Qin F, Yuan J. Current approaches to the diagnosis of vascular erectile dysfunction. Transl Androl Urol. 2020;9(2):709-21. DOI:10.21037/tau.2020.03.10</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Krzastek SC, Bopp J, Smith RP, Kovac JR. Recent advances in the understanding and management of erectile dysfunction. F1000Res. 2019;8:F1000 Faculty Rev-102. DOI:10.12688/f1000research.16576.1</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lurz K, Dreher P, Levy J, et al. Low-intensity shockwave therapy in the treatment of erectile dysfunction. Cureus. 2020;12(11):e11286. DOI:10.7759/cureus.11286</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Lee YC, Yang TD, Chen WC, et al. Synergistic efficacy of low-intensity extracorporeal shock wave and platelet-rich plasma on erectile dysfunction. Bulletin of RSMU. 2024;(6):154-61. DOI:10.24075/brsmu.2024.054</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tao R, Chen J, Wang D, et al. The Efficacy of Li-ESWT combined with VED in diabetic ED patients unresponsive to PDE5is: A single-center, randomized clinical trial. Front Endocrinol (Lausanne). 2022;13:937958. DOI:10.3389/fendo.2022.937958</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>EAU Guidelines on Sexual and Reproductive Health: Management of erectile dysfunction. European Association of Urology. 2025. Available at: https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/management-of-erectile-dysfunction. Accessed: 05.08.2025.</mixed-citation></ref></ref-list></back></article>
